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SUMMARY
Colorectal cancer (CRC) initiation and growth is often
attributed to stem cells, yet little is known about the
regulation of these cells. We show here that a sub-
population of Prox1-transcription-factor-expressing
cells have stem cell activity in intestinal adenomas,
but not in the normal intestine. Using in vivo models
and 3D ex vivo organoid cultures of mouse ade-
nomas and human CRC, we found that Prox1 dele-
tion reduced the number of stem cells and cell
proliferation and decreased intestinal tumor growth
via induction of annexin A1 and reduction of the
actin-binding protein filamin A, which has been impli-
cated as a prognostic marker in CRC. Loss of Prox1
also decreased autophagy and the survival of
hypoxic tumor cells in tumor transplants. Thus,
Prox1 is essential for the expansion of the stem cell
pool in intestinal adenomas and CRC without being
critical for the normal functions of the gut.
INTRODUCTION
Colorectal cancer (CRC) is one of the leading causes of cancer
mortality in Western countries. In most CRC patients, an initial
mutation occurs in the APC or CTNNB1 gene, leading to activa-
tion of the b-catenin/TCF (canonical Wnt) pathway (Fearon,
2011; Fodde and Smits, 2001). In the crypts of the normal gut,
the b-catenin/TCF pathway is active in Paneth cells, in transit-
amplifying (TA)/progenitor cells that have a limited proliferative
capacity, and in Lgr5+ intestinal stem cells (Clevers, 2006).
Lgr5+ cells are capable of efficiently initiating adenoma formation
upon mutation of the Apc gene (Barker et al., 2009). In addition,
progenitors of intestinal epithelial cells can convert to a stem
cell-like phenotype and contribute to the initiation of CRC under
inflammatory conditions (Schwitalla et al., 2013). These studies
indicate that the acquisition of a stem cell-like phenotype is
critical for CRC tumorigenesis.
Intestinal adenomas are highly heterogenous, containing both
proliferating and differentiating cells, and they are continuously
maintained by a dedicated cell population, the so-called cancer
stem cells (Sampieri and Fodde, 2012; Schepers et al., 2012).
Although neoplastic cells are characterized by increased cell
proliferation and limited cell differentiation capacity, their
detailed differentiation pathways in CRC are poorly known.
Expression of the Lgr5 gene has been shown to mark a cell pop-
ulation with stem cell properties in mouse intestine and in intes-
tinal adenomas (Barker et al., 2007; Schepers et al., 2012).
Furthermore, the intestinal stem cell signature, including LGR5
expression, identifies CRC stem cells and predicts disease
relapse also in human CRC patients (Kemper et al., 2012; Mer-
los-Sua´rez et al., 2011).
After the genetic lesion that activates the Wnt signal transduc-
tion pathway and abnormal cell proliferation, additional muta-
tions accumulate slowly to promote adenoma progression
toward CRC, tumor invasion, and metastasis (Sampieri and
Fodde, 2012). Highly elevated Wnt activity after Apc deletion in-
duces expression of the homeobox transcription factor Prox1 in
intestinal tumor cells. When Prox1 was deleted in mice with an
Apc mutation, adenoma growth and development of dysplasia
in the tumor epithelium was inhibited (Petrova et al., 2008). In-
terestingly, Prox1 upregulation after loss of the tp53 tumor sup-
pressor contributes to intestinal tumor progression in some
model systems (Elyada et al., 2011).
Here, we analyzed the mechanism of Prox1-induced intestinal
adenoma progression in microsatellite-stable tumor models. We
found that a subpopulation of Prox1+ cells displays stem cell
activity in adenomas/CRC, but not in the normal intestinal
epithelium. Furthermore, Prox1 deletion reduced the size of the
Lgr5+ adenoma and CRC stem cell populations, and stem cell
activity and led to reduced growth and decreased tumor cell sur-
vival in an unfavorable microenvironment.
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RESULTS
Prox1 Expression Is Induced in Lgr5+ Cells upon Apc
Gene Deletion
To characterize Prox1-expressing cells in the pathogenesis of in-
testinal adenomas, we induced an acute deletion of the Apc
gene throughout the whole intestinal epithelium in Apcflox/flox;
villin-CreER (VApc) mice by a single tamoxifen injection
(VApcD/D). As expected, Paneth cells, marking the crypt
bottoms in the wild-type (WT) small intestine, were dislocated
toward the lumen in most of the Apc-deleted crypts, and ex-
pansion of the cell population with an active Wnt signaling
pathway was detected by EphB2 immunostaining 6 days after
the tamoxifen injection (Figures S1A and S1B) (Batlle et al.,
2002). Most crypts contained scattered Prox1+ cell clusters
intermingled with lysozyme-positive Paneth cells (Figure S1A).
Cyclin D1 marks the proliferating cell population, including the
progenitor cells in WT intestine (Gregorieff and Clevers, 2005).
In line with previously published results, the cyclin D1+ cell pop-
ulation expanded after the Apc deletion (Sansom et al., 2005)
(Figures S1A and S1B). CyclinD1high cells were located
frequently close to the Prox1+ cells; however, Prox1+ cells
were not cyclin D1high in VApcD/D mice and in tumors from
Apcmin/+ mice (Figures S1C and S1D) or from CRC patients (Fig-
ure S1E). Similarly to the in vivo experiments, when we isolated
intestinal organoids from the VApc mice and induced Apc
gene deletion in 3D Matrigel culture by the addition of 4-hy-
droxy-tamoxifen (4-OH-Tam), the organoids showed emerging
Prox1+ cell clusters 2 days after 4-OH-Tam treatment (Fig-
ure S1F). At later time points, Prox1 expression was maintained
in isolated cell clusters (Figure S1G).
A recent study reported that PROX1 is part of the Wnthigh CRC
stem cell gene signature (de Sousa EMelo et al., 2011).We found
that Prox1 was expressed in the earliest histological adenoma-
tous lesions, the aberrant crypt foci, of the Apcmin/+ mice, which
represent a widely used mouse intestinal adenoma model (Fig-
ure 1A). To examine Prox1 expression in the Lgr5+ intestinal
stem cells of the adenomas, we produced Apcflox/flox; Lgr5-
EGFP-IRES-CreER (LApc) mice and induced Apc deletion in the
stem cells (LApcD/D). LApc and Lgr5-EGFP-IRES-CreER mouse
intestines show green EGFP signals in the Lgr5+ stem cells at the
crypt bottom (Barker et al., 2007). Notably, the cyclin D1high cell
clusters were enriched mostly among the Lgr5low and Lgr5 cell
populations in the intestinal adenomas after Apc deletion, con-
firming that cyclin D1high cells do not accumulate in the stem
cell population (Figure 1B). Prox1 was expressed in some of
the Paneth cells in the ileum and Prox1+ cells in the normal intes-
tine were often located near the Lgr5+ cells (Figure S1H; Fig-
ure 1C), but there was no overlap between the EGFP and
Prox1 signals in the untreated intestine or during epithelial repair
at 4, 6, and 10 days after 6 Gy irradiation (Figure S1I and data not
shown). However, 5 days after tamoxifen injection, Prox1
expression was observed also in the Lgr5+ cells of the devel-
oping adenomas (Figure 1C). Taken together, these results
indicate that Prox1 is induced during the early steps of tumori-
genesis in adenoma cells, including Lgr5+ stem cells, both in vivo
and ex vivo, but not in the cyclin D1high cells that may represent
more differentiated or intestinal progenitor-like cells.
A Subpopulation of the Prox1+ Cells Has Stem Cell
Activity in Intestinal Adenomas, but Not in the Normal
Intestine
To study if Prox1+ cells have stem cell activity in intestinal ade-
nomas, we produced Prox1-CreER (Srinivasan et al., 2007);
Rosa26-tdTomatoflox/Stop/flox; Apcmin/+ mice for lineage-tracing
experiments. In this model, a single tamoxifen injection activated
the Cre allele, resulting in expression of the tdTomato red fluo-
rescent protein only in the Prox1+ tumor cells 1 day after the
tamoxifen injection (Figure 1D), confirming that the activation
of the Cre protein is specific to the Prox1-expressing tumor cells.
However, 28 days after tamoxifen injection, we observed that the
Prox1+ cells had produced adjacent tdTomato+/Prox1 prog-
eny, which occasionally stained for mucin2 of goblet cells or
for lysozyme of Paneth cells, indicating that Prox1+ tumor cells
can give rise to differentiated cells in the intestinal adenomas
(Figures 1D and 1E).
In the Prox1-CreER; Rosa26-tdTomatoflox/Stop/flox; Apcmin/+
mice, Prox1+ epithelial cells were very rarely labeled outside of
the tumors after tamoxifen injection. In order to activate the
lineage marker more effectively, we used mice harboring a
Prox1-CreER bacterial artificial chromosome at an ectopic
genomic site (Bazigou et al., 2011). In these mice, only sporadic
Prox1+ intestinal epithelial cells were positive for the red lineage
marker 7 days after tamoxifen treatment (Figure 1F). Further-
more, Prox1 deletion in the intestinal epithelium of Prox1flox/flox;
villin-CreERmice (VPD/D) did not result in any obvious phenotype
(see Supplemental Results). These data indicate that a subpop-
ulation of the Prox1+ cells has stem cell properties in adenomas,
but not in normal intestine.
Prox1 Deletion Leads to Loss of Lgr5+ Stem Cells in
Intestinal Adenomas
To analyze the significance of Prox1 specifically in adenoma
stem cells, we deleted Apc and Prox1 in the Lgr5+ cells of
Apcflox/flox; Prox1flox/flox; Lgr5-EGFP-IRES-CreER (LApcP) mice.
In order to obtain an efficient deletion, tamoxifen was injected
during 2 consecutive days and the size of the Lgr5+ cell popula-
tion was analyzed 21 days thereafter. Interestingly, the majority
of the adenomas contained some Prox1+ cells, suggesting an
incomplete deletion of Prox1 in the crypt stem cells (Figure 2A).
However, the Prox1+ adenomas contained fewer Lgr5+ cells in
tamoxifen-treated LApcP (LApcPD/D) mouse intestines than in
the LApcD/D controls (Figure 2B). Furthermore, the number of
stem cells was even lower in the Prox1 crypt-like structures
that contained dislocated Lgr5+ cells both in the small and large
intestine, indicating that successful Prox1 deletion inhibits the
expansion of Lgr5+ cells in the adenomas (Figure 2B).
To further test this hypothesis ex vivo, we used LApcD/D and
LApcPD/D organoids. The Wnt-agonist R-Spondin1 is required
for the survival and growth of the WT (LApc or LApcP) intestinal
organoids (Sato et al., 2009). Without R-Spondin1, only organo-
ids with Apc deletion and resulting active b-catenin/TCF
pathway survive beyond 4 days (Wiener et al., 2014). Almost all
the Prox1+ cells of LApcD/D organoids were Lgr5-EGFP positive
8 days after the addition of 4-OH-Tam without R-Spondin1 (Fig-
ure 2C). However, therewas amarked reduction in the number of
viable organoids 8 days after the simultaneous deletion of Apc
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and Prox1 in the Lgr5+ cells (Figures 2D–2F). The viable organo-
ids contained some Prox1+ cells at this time point (Figure 2C),
suggesting that Prox1 deletion was not complete in the organo-
ids. Since Prox1 was not expressed in the Lgr5+ stem cells
before Apc was deleted, but only after 5 days of Apc deletion
in vivo, these data indicate that loss of Prox1 expression does
Figure 1. Prox1 Expression and Cell Line-
age Tracing in Intestinal Adenomas after
Apc Deletion
(A) Prox1 expression in an aberrant crypt focus in
the Apcmin/+ intestine.
(B) Lgr5-EGFP and cyclin D1 staining in LApc
mouse intestine before (LApc) and 21 days after
the addition of tamoxifen (LApcD/D). Note some
overlap of staining in the Lgr5low cell population
(dotted areas).
(C) Distribution of the Lgr5-EGFP and Prox1 sig-
nals in the intestinal epithelium of LApc mice after
the injection of a single dose of tamoxifen. Note
the lack of overlap between Prox1+ (arrowhead)
and Lgr5+ cells at day 0 and the overlap (dotted
areas) at days 5 and 21.
(D and E) Immunostaining of adenomas derived
from Prox1-CreER; Rosa26-tdTomatoflox/Stop/flox;
Apcmin/+ mice for the indicated proteins after a
single tamoxifen injection (cell lineage tracing).
The arrows mark tdTomato+/Prox1/Mucin2+ or
tdTomato+/Prox1/Lysozyme+ cells.
(F) Prox1 and tdTomato signals in Prox1-CreER;
Rosa26-tdTomatoflox/Stop/flox mice 7 days after
tamoxifen injection. The arrows indicate the rare
labeled Prox1+ cells in the normal intestinal
epithelium.
Scale bars represent 20 mm (B and D–F) or 50 mm
(A and C). See also Figure S1.
not influence the tumor initiation fre-
quency, but instead, it inhibits the ex-
pansion of the Lgr5+ adenoma cell
population.
To directly address the connection be-
tween Prox1 and stem cell number in
another ex vivo organoid culture system,
we isolated organoids from Apcflox/flox;
villin-CreER (VApc) and Apcflox/flox;
Prox1flox/flox; villin-CreER (VApcP) mice,
where Apc and/or Prox1 are deleted in
the whole intestinal epithelium, including
the progenitor cells. Deletion of Prox1
alone from the whole intestinal epithelium
derived from the Prox1flox/flox; villin-CreER
mice did not induce morphological
changes in the organoids (Figure S2A).
However, deletion of both Apc and
Prox1 (VApcPD/D) from the organoids
increased the relative expression level of
the progenitor markers Nol1 and Wdr3
(Van der Flier et al., 2007) and the relative
number of cyclin D1high cells in compari-
son with organoids with only Apc deletion
(Figures 3A–3C). As in the tamoxifen-injected VApcD/Dmice, the
Prox1+ cells were cyclin D1low (Figure 3B). Furthermore, RNAs
encoding the Wnt-target intestinal stem cell signature genes
Lgr5, Tnfrsf19, and Ascl2 were decreased upon Prox1 deletion,
whereas c-Myc RNA was not changed (Figure 3C and data not
shown). Microarray analysis of VApcD/D and VApcPD/D cultures
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7 days after the addition of 4-OH-Tam indicated decreased in-
testinal stem cell markers and changes in the expression levels
of specific Wnt targets in the VApcPD/D organoids (Figure S2B).
These data suggested thatProx1 deletion decreases the number
of adenoma stem cells, resulting in a skewed enrichment of the
progenitor population in the organoids 7 days after Apc deletion.
Indeed, the Prox1-deleted organoids were less efficient in form-
ing new organoid subcultures when they were dissociated to
small clusters containing approximately four to seven cells
(Figure 3D).
PROX1 Silencing Decreases Stem Cells in Human CRC
Organoids
To model the effect of PROX1 on stem cell activity in CRC pro-
gression, we chose to use the human SW1222 cell line (mutant
CRC genes in this cell line are listed in Table S1). This cell line
Figure 2. Prox1 Deletion from the Lgr5+ Adenoma Cells Inhibits the Expansion of the Stem Cell Pool
(A) Lgr5-EGFP and Prox1 signals in untreated LApc mouse intestine and in LApcPD/D intestine 21 days after tamoxifen addition. The arrowhead marks a Prox1
crypt with dislocated Lgr5+ cells (implicating Apc deletion). The asterisks mark Prox1+ crypts.
(B) The number of Lgr5+ cells per the various types of crypts in the small intestine or colon (Kruskal-Wallis test, n = 25 from three mice). The boxplot indicates the
minimum, the first quartile, median, third quartile, and maximum.
(C) Lgr5-EGFP and Prox1 signals in the LApcD/D and LApcPD/D organoids.
(D and E) Viable LApcD/D and LApcPD/D organoids (D, arrowheads) and their quantification (E).
(F) Prox1 RNA level.
For (C)–(F), the samples were analyzed 8 days after the addition of 4-OH-Tam and 6 days after the removal of the growth factors. Scale bars represent 20 mm (C) or
100 mm (A and D). Mean + SD are shown (E and F).
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is enriched for stem cells that can self-renew and differentiate
into multiple lineages (Yeung et al., 2010). While the ‘‘small
colonies’’ in SW1222 cell-derived 3D cultures have a limited
growth potential and lack lumens, the large glandular ‘‘megacol-
onies’’ produce crypt-like structures consisting of polarized cells
surrounding a central lumen (Yeung et al., 2010). Lumens are
stem cell-dependent structures present in well-differentiated
tumors and likewise in ex vivo and in vitro 3D cultures from
human and mouse adenomas and stem cell-containing CRC
cell lines (Ashley et al., 2013).
Since the SW1222 cells have heterogenous PROX1 and nu-
clear b-CATENIN expression levels (Figure S2C), we isolated
subclones with a low (PROX1low) or a high (PROX1high) percent-
age of PROX1+ cells (Figure S2D). We then silenced PROX1 in
the PROX1high clone by two different lentiviral short hairpin
RNAs (shRNAs) (Figure S2E and data not shown). Interestingly,
the PROX1-silenced SW1222-PROX1high cells formed a strik-
ingly reduced number of glandular colonies (Figure 3E), suggest-
ing that PROX1 silencing has a profound effect on CRC stem cell
activity. Furthermore, PROX1 silencing decreased the number
of lumens in the glandular colonies derived from SW1222-
PROX1high cells (Figure 3F). After 12 days of 3D culture, the
LGR5 and TNFRSF19 RNAs were decreased, whereas no
changes were observed in the expression of other WNT-target
genes, such as MYC (Figure 3G). PROX1 silencing in CRC
patient-derived organoids also resulted in decreased frequency
of new lumen-containing organoids (Figure 3H). Notably, the
shPROX1 organoids formed small colonies without lumens (Fig-
ure 3H). Similarly to the SW1222 cell line, PROX1 silencing in
CRC patient-derived organoids resulted in a marked reduction
of LGR5 and TNFRSF19 RNA levels (Figure 3I), even in the
presence of a KRAS mutation (see Supplemental Experimental
Procedures). LGR5 in situ hybridization further indicated that
PROX1 silencing decreases the number of CRC stem cells (Fig-
ures 3J and 3K). Notably, there was no difference in the LGR5
RNA in PROX1-silenced SW1222 cells in 2D culture (data not
shown), thus ruling out the possibility that LGR5 is a direct
PROX1 target. These results suggest that loss of PROX1 de-
creases the CRC stem cells also in human CRC, and that this
is independent of the presence of KRAS mutations.
PROX1+ Tumor Cells Proliferate Less Than Prox1
Tumor Cells, yet PROX1 Deletion Leads to Decreased
Cell Proliferation in the Tumors In Vivo
To test the in vivo significance of our findings, we implanted
SW1222-PROX1high cells and their PROX1-silenced counter-
parts subcutaneously into immunocompromised (NOD scid
gamma [NSG]) mice and monitored tumor growth. Similarly
to the Prox1-deleted intestinal adenomas (Petrova et al.,
2008), the PROX1-silenced tumors grew slower than controls
transduced with scrambled shRNA (Scr) at this ectopic
implantation site (Figure 4A). Notably, we detected 60% fewer
tumor nests in the PROX1-silenced samples as compared
to Scr controls (200.4 ± 46.8 and 70.9 ± 11.8 tumor nests,
respectively; p < 0.01) when they were excised 21 days after
the implantation. Unlike the scrambled shRNA-transduced
tumors, the PROX1-silenced tumors contained tumor nests
with only few glandular structures (Figure 4B). Similarly to the
PROX1-silenced SW1222 cells, subcutaneously implanted
Prox1-deleted mouse VApcPD/D organoids grew slower and
contained fewer glands than VApcD/D organoids (Figures 4C
and 4D). Prox1 deletion decreased Lgr5 and Tnfrsf19 RNAs,
but not of Myc RNA in the tumors, confirming our ex vivo re-
sults (Figure 4E).
Intestinal epithelial progenitor cells proliferate rapidly, but only
for a limited number of cell cycles (Gregorieff and Clevers, 2005).
Careful analysis of the Prox1+ and Prox1 cells in control
SW1222-PROX1high or in VApcD/D organoid-derived tumors
indicated that the Ki67+ proliferating cells were enriched in the
Prox1 cell population (Figures S3A and S3B), suggesting that
most of the Prox1+ cells are nonproliferative or slowly prolifer-
ating. Interestingly, the Prox1+/Lgr5+ cell population had a higher
frequency of Ki67+ cells than the Prox1+/Lgr5 population in the
LApcD/D intestine (Figure 4F), indicating that the rapidly prolifer-
ating Prox1+ cells are enriched in the Lgr5+ population. Similarly,
bromodeoxyuridine labeling of two highly proliferating organoid
cultures (VApcD/D and VCKID/D) showed that only a small
proportion of the Prox1+ cells proliferated (Figure S3C). VCKID/D
organoids are deleted of tp53 and Csnk1a1, encoding casein
kinase Ia (CKIa), which phosphorylates b-catenin, targeting it
to ubiquitin-mediated destruction; thus, the VCKID/D organoids
display activated Wnt signaling pathway (Elyada et al., 2011).
Whereas Prox1+ cells appeared to proliferate slowly, we
observed a decreased overall frequency of Ki67+ tumor cells in
subcutaneously growing PROX1-silenced SW1222-PROX1high
tumors, in Prox1-deleted VApcPD/D organoid tumors in NSG
mice, and in the Lgr5+ cells of LApcPD/D intestinal tumors (Fig-
ure 4G; Figure S3D). A possible explanation for these apparently
contradictory data is that Prox1 deletion results in decreased
proliferation in the stem cell population, which leads to exhaus-
tion of the CRC stem cell pool and consequently to a decrease of
the overall ratio of proliferating cells. Indeed, a slower prolifera-
tion rate of the PROX1-silenced SW1222-PROX1high cell-derived
organoids was observed only after a 14-day culturing period,
when the PROX1+ organoids already had an extensive lumen
forming activity, but not at 6 days (Figure S3E). This indicates a
delayed effect of PROX1 silencing on the overall cell proliferation
in the organoids, in line with the idea that PROX1 influences
tumor growth by regulating the size of the proliferating stem
cell pool.
The PROX1- (adherent) cells of the SW480 CRC cell line
(SW480A) are unable to initiate subcutaneous tumors in NSG
mice, whereas the PROX1+ cells (SW480R) are round, form
cell clusters, and are tumorigenic (Petrova et al., 2008). To
test if PROX1 silencing in already established CRC xenografts
regulates stem cells, we implanted cells from the PROX1+
stem cell-like SW480R subclone, expressing a doxycycline-
inducible PROX1 shRNA construct (SW480R-sh) (Petrova
et al., 2008), into NSG mice. Doxycycline treatment was
started 8 days after subcutaneous injection, when the tumors
were already visible. We observed reduced growth of the
PROX1-silenced tumors after day 16 (Figures 4H and 4I), at a
time point when the LGR5 RNA level had already markedly
decreased in the doxycycline-treated tumors (Figure 4J). These
data suggest that PROX1 regulates stem cells also in estab-
lished tumors.
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Figure 3. Prox1 Deletion Leads to Reduced Stem Cell Activity in Ex Vivo Organoids
(A) The schematic outline of the mouse organoid experiments. GF, growth factors.
(B) Prox1 and cyclin D1 immunostaining of sections from VApcD/D and VApcPD/D organoids 7 days after the deletion and 5 days after removing R-Spondin1 from
the culture medium.
(C) RNA levels of progenitor markers (Nol1, cyclin D1, andWdr3), stem cell markers (Lgr5 and Tnfrsf19), and Myc in VApcD/D and VApcPD/D organoids analyzed
by real-time quantitative PCR (qRT-PCR).
(D) The organoid initiating frequency of VApcD/D and VApcPD/D organoids.
(E) The proportion of glandular colonies derived from 1,000 SW1222-PROX1high cells (transduced with Scr, sh1, or sh2 PROX1 shRNA lentivirus).
(F) The number of lumens in the glandular colonies derived from Scr or shPROX1-transduced (sh1, sh2) SW1222-PROX1high cells at day 14 (n = 10 for sh1 and
n = 12 for sh2). The lumens (asterisks) were detected by phalloidin staining and counted in optical sections of confocal microscopic images. The boxplot indicates
the minimum, the first quartile, median, third quartile, and maximum.
(G) Real-time qPCR of the indicated RNAs from SW1222-PROX1high cell-derived organoids, transduced with shPROX1 or Scr lentivirus and grown in Matrigel for
14 days.
(legend continued on next page)
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PROX1 Silencing Increases Annexin A1 Expression in
Multiple CRC Models
To determine which genes are responsible for the effect of
PROX1 on the adenoma/CRC stem cells, we tested PROX1-
(H) Images and the relative lumen-containing organoid initiating frequency of Scr and shPROX1 lentivirus-transduced human organoids derived from CRC
patients. The GFP signal shows the lentiviral transduction efficiency.
(I) RNA levels of the indicated genes in human CRC patient-derived organoids, transduced with Scr or shPROX1 lentivirus. Note that while sample 1 contains the
G12D clinically relevant mutation in the KRAS gene, samples 2 and 3 are wild-type.
(J and K) LGR5 in situ hybridization and quantification of LGR5+ cells in the Scr and shPROX1-transduced SW1222-PROX1high clone.
Scale bars represent 100 mm (B) or 50 mm (E, F, H, and K). Mean + SD (C–E and G–I) or mean + SEM (J) are shown. See also Figure S2.
Figure 4. PROX1 Regulates the Number of
Stem Cells via Cell Proliferation
(A) Growth curve of subcutaneous tumors derived
from Scr or shPROX1-transduced SW1222-
PROX1high cells in NSG mice (n = 10).
(B) PROX1 and E-CADHERIN immunostaining and
HE staining of tumor sections 21 days after sub-
cutaneous injection of SW1222-PROX1high cells
into NSG mice. The dashed line indicates the tu-
mor border, the arrowheads point to degenerating
glandular structures and the asterisk marks
necrotic area.
(C–E) Immunostaining, tumor volume (C and D)
and RNA quantification (E) of VApcD/D (black
columns) and VApcPD/D (red columns) organoid-
derived tumors 12 and 28 days after their subcu-
taneous injection into NSG mice (confocal 3D
reconstruction). Note the more complex glandular
structure of the VApcD/D tumors (asterisks).
(F and G) The percentage of proliferating (Ki67+)
cells among the Prox1+ cells in the Lgr5+ and
Lgr5 populations in the intestinal epithelium of
LApcD/Dmice 21 days after Apc deletion (n = 10–
12) (F). The percentage of Ki67+ cells in the Lgr5+
cell population in the intestinal epithelium of
LApcD/D and LApcPD/D mice (n = 9–11) (G). The
boxplots indicate the minimum, the first quartile,
median, third quartile, and maximum (F and G).
(H–J) Growth of subcutaneous SW480R-sh tu-
mors in NSG mice (H) with or without doxycycline
(n = 10). Doxycyline treatment from day 8 (blue
arrow) to day 16 (red arrow) after cell implantation
was used for the silencing of PROX1. Immuno-
staining (I) and quantitative RT-PCR (qRT-PCR) (J)
analyses at day 16.
Scale bars represent 50 mm (B) and 100 mm (B, D,
and I). Mean + SD (C, E, and J) or mean + SEM
(A and H) are shown. See also Figure S3.
regulated candidate genes based on
the microarray data derived from the
SW480R subclone (Petrova et al., 2008).
Based on our initial results, we focused
further on the calcium-dependent phos-
pholipid binding protein Annexin A1
(ANXA1), which has been shown to inhibit
breast cancermetastasis (Maschler et al.,
2010). PROX1 suppressed ANXA1 RNA
(4.21 ± 0.08-fold, mean ± SD) and protein
expression in SW480R-sh cells (Fig-
ure S4A). Anxa1 was increased after 4-OH-Tam addition to
VApc organoids and even further elevated when also Prox1
was deleted (Figure 5A; Figures S4B and S4C), suggesting that
Prox1 suppresses Anxa1 expression. Furthermore, the Prox1
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cells showed more intense Anxa1 staining than Prox1+ cells in
tumor sections from Apcmin/+ mice (Figure S4D).
We observed a mutually exclusive staining for Anxa1 and
Prox1 in tumors from VCKID/Dmice and in human CRC samples
(Figures 5B and 5C). Furthermore, the Lgr5+ intestinal stem cells
in the LApcmice showed very little or no epithelial Anxa1 expres-
sion before Apc deletion (Figure S4E). They contained a low level
of Anxa1 after tamoxifen injection, whereas the Anxa1high cells
were negative for Lgr5 in the resulting adenomas (Figure S4F).
Importantly, transfection of a dominant-negative TCF4 (tran-
scription factor 7-like 2 [TCF7L2]) construct, aWnt pathway sup-
pressor to the PROX1 subclone of the SW480 CRC cell line
(SW480A) (Petrova et al., 2008), led to suppression of ANXA1
expression (Figure 5D). These data indicate that Anxa1 is mini-
mally expressed in the normal intestinal epithelium, where the
activation of the Wnt pathway after Apc deletion increases
Anxa1 expression, which is then suppressed by the induction
of Prox1 in the tumor cells.
ANXA1 Silencing Mimics the Effects of PROX1 in CRC
Wenext tested the possibility that the strong ANXA1 suppression
mediates the effects of PROX1, such as the associated rear-
rangement of the actin cytoskeleton, changes in cell shape,
and adherence to the culture plates (Petrova et al., 2008). Indeed,
ANXA1 overexpression in the SW480R subclone induced an
elongated cell shape and increased the number of tightly
adherent cells, whereas ANXA1 suppression resulted in rear-
rangement of the actin cytoskeleton, rounded cell shape, and
decreased adherence (Figures S5A–S5C). Interestingly, Anxa1
silencing in VApcD/D organoids increased the Lgr5 and Tnfrsf19
stem cell marker RNAs, without affecting Myc (Figure 5E).
Although ANXA1 silencing had no effect on PROX1 expression
in SW1222-PROX1low or SW480 cells in 2D culture (data not
shown), it resulted in increased lumen formation (Figure 5F),
upregulation of TNFRSF19 and LGR5 RNAs, and increase of
LGR5+ cells in 3D organoids derived from shANXA1-transduced
cells (Figures 5G and 5H). In contrast, ANXA1 overexpression
in SW1222-PROX1high cells decreased the proportion of glan-
dular colonies, the number of organoid lumens, and LGR5
and TNFRSF19 RNA levels when compared to the controls (Fig-
ures S5D–S5F). Furthermore, the ANXA1-silenced SW1222-
PROX1low cell-derived tumors grew faster than control tumors,
contained more Ki67+ cells, and were composed of larger
tumor nests with multiple lumens organized into labyrinth-like
structures (Figure 5I; Figure S5G). Similar to the effect of
PROX1, ANXA1 silencing in SW1222 cell-derived organoids
was associated with enhanced cell proliferation only after
16 days, when the organoids showed extensive outpocketing
and lumen formation, but not at day 6 (Figure S5H). These data
indicate that ANXA1 silencing mimics the effects of PROX1
expression, leading to an expansion of the stem cell pool via
increased proliferation.
Silencing the Actin-Binding Protein FILAMIN A
Decreases Stem Cells in CRC
Reanalysis of the microarray data derived from the SW480R
subclone showed that focal adhesion and regulation of actin
cytoskeleton were the top Kyoto Encyclopedia of Genes and
Genomes gene pathway categories affected when PROX1 was
silenced (data not shown). Thus, we searched for PROX1-regu-
lated genes directly affecting the cytoskeleton among published
CRC stem cell gene sets (de Sousa EMelo et al., 2011) and prog-
nosis markers in CRC subgroups (Sadanandam et al., 2013). We
found the gene encoding the actin-binding protein filamin A
(FLNA) in both gene sets. FLNA connects actin filaments to
transmembrane receptors, including b1 integrin, modulates cell
migration, and functions as a central mechanotransduction
element of the cytoskeleton (Ehrlicher et al., 2011; Zhou et al.,
2010). Interestingly, we found highly increased Flna expression
in the Prox1+ and Lgr5+ tumor cells (Figure 6A and data not
shown) and a correlation between PROX1 and FLNA levels in
the SW1222-PROX1high cell-derived organoids (Figure S5I).
FLNA was also upregulated in the ANXA1-silenced organoids
(Figures 6B and 6C). Furthermore, PROX1 silencing in the
SW1222-PROX1high and CRC patient-derived organoids re-
sulted in markedly decreased FLNA RNA (Figure 6D) and protein
(Figure 6E).
Because both PROX1 and ANXA1 regulated FLNA expression
in intestinal adenomas and in CRC 3D organoids, we studied
FLNA function by silencing its expression in VApcD/D organoids
and in SW1222-PROX1high cells. This led to reduced Lgr5 and
Tnfrsf19 RNAs (Figure 6F), to a decrease of SW1222 cell-
derived glandular colonies and lumens (Figure 6G), and to a
decreased number of Ki67+ cells in the organoids (Figure 6H).
Surprisingly, FLNA silencing did not affect the growth of the cells
in 2D culture conditions (data not shown). Overall, these results
suggest a model where the loss of Prox1 leads to an elevated
Anxa1 level and a reduction in Flna, which limit the expansion
Figure 5. ANXA1 Silencing in CRC Leads to Elevated Stem Cell Activity and Tumor Growth
(A) Immunostaining of VApcD/D and VApcPD/D organoids for the indicated proteins.
(B and C) Immunoperoxidase staining of sections from (B) VCKID/D tumors and (C) from a tumor of a CRC patient (n = 5).
(D) ANXA1 expression in SW480 cells transfected with a dominant-negative dnTCF4-FLAG or an unrelated control construct (TIE1-FLAG). The arrowheads
indicate transfected cells.
(E) RNA analysis of Scr and shAnxa1-transduced VApcD/D organoids (black and green columns, respectively).
(F) Number of lumens in SW1222-PROX1low subclone-derived organoids, transduced with either Scr or shANXA1-expressing lentivirus, stained with fluorescent
phalloidin and counted from optical sections of confocal images. The white asterisks mark the lumens (n = 11 for sh(1) and n = 25 for sh(2)). The boxplot indicates
the minimum, the first quartile, median, third quartile and maximum.
(G and H) RNA levels of the indicated transcripts (G) and LGR5 in situ hybridization (H) (red signal) in SW1222-PROX1low-derived organoids, grown in Matrigel
for 16 days.
(I) Growth curves (n = 6), histological analysis and immunostaining of SW1222-PROX1low tumors growing subcutaneously in NSG mice.
For the staining, the tumors were isolated on day 11 after the implantation. Scale bars represent 100 mm (A–D) or 50 mm (F, H, and I). Mean + SD (E and G) or
mean + SEM (H and I) are shown. See also Figures S4 and S5.
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of the adenoma/CRC stem cell population via decreasing cell
proliferation.
PROX1 Silencing Reduces Cell Survival in Hypoxic
Tumor Xenografts
Interestingly, when grown to a large size in Matrigel culture
(>150 mm diameter, >5 days after subculture) or injected subcu-
taneously into NSG mice, Prox1-deleted VApcPD/D organoids
contained more apoptotic cells than VApcD/D organoids (Fig-
ure 7A). Also, we detected an intense staining for the apoptosis
marker active CASPASE-3 inside the PROX1-silenced SW1222-
PROX1high cell-derived subcutaneously growing tumors that
were positive for the hypoxia marker carbonic anhydrase IX,
but not at the tumor margin (Figure 7B and data not shown), sug-
gesting reduced tumor cell survival in the ischemic/hypoxic
tumor interior. Interestingly, we found no difference in the endo-
mucin+ blood vessel density between Scr and shPROX1 tumors,
even when vascular endothelial growth factor (VEGF) was over-
expressed in the tumor cells (Figures S6A and S6B). However,
the shPROX1 tumors were smaller than the Scr tumors,
even when VEGF was overexpressed in the tumor cells and
VEGF failed to rescue the large necrotic areas inside the
Figure 6. Silencing the Actin-Binding Protein Filamin A Inhibits Stem Cell Activity
(A) Immunostaining for filamin A (Flna) and Prox1 in an intestinal adenoma of Apcmin/+ mice.
(B and C) FLNA staining (B) and qRT-PCR (C) from scrambled and shANXA1-transduced SW1222-PROX1low cell-derived organoids 14 days after 3D seeding.
(D) FLNA RNA in CRC patient-derived and SW1222-PROX1high cell-derived organoids, transduced with Scr or shPROX1 lentivirus (qRT-PCR).
(E) Immunostaining for PROX1 and FLNA in Scr or shPROX1-transduced, SW1222-PROX1high cell-derived organoids, cultured for 7 days inMatrigel (confocal 3D
reconstructions).
(F) The levels of the indicated RNAs in VApcD/D organoids 10 days after transduction with Scr or shFlna lentivirus (qRT-PCR).
(G) The proportion of glandular colonies and the number of lumens (n = 8 for sh(1) and n = 14 for sh(2)) in SW1222 cell-derived organoids, transduced with the
indicated lentivirus.
(H) The percentage of Ki67+ cells in Scr (black box) or shFLNA-transduced (gray box) SW1222 cell-derived organoids after 9 days of 3D culturing, counted from
confocal optical sections (n = 12).
The boxplots in (G) and (H) indicate the minimum, the first quartile, median, third quartile, and maximum. Mean + SD are shown (C, D, F, and G). Scale bars
represent 50 mm (A and B) or 25 mm (E). See also Figure S5.
1952 Cell Reports 8, 1943–1956, September 25, 2014 ª2014 The Authors
PROX1-silenced tumors (Figures S6A and S6B). Thus, the pres-
ence of the large necrotic areas in the shPROX1 tumors could
not be explained by the lack of angiogenic factors.
Although ANXA1 silencing mimicked several of the effects of
PROX1 in the intestinal adenoma and CRC models, the
apoptosis rate in the ANXA1-silenced subcutaneously growing
tumors was not significantly affected when analyzed 9 or
24 days after implantation (data not shown). This raised the pos-
sibility that in unfavorable conditions also alternative pathways
contribute to the apoptosis in the shPROX1 tumors. Autophagy
is an essential cellular process for the survival of cells under hyp-
oxia or nutrient deprivation (Sato et al., 2007). Interestingly,
PROX1 silencing in the SW480R cells resulted in a decrease of
the autophagy-associated LC3-II protein both in normal medium
and in starvation conditions (Figures 7C and 7D). Furthermore,
lack of PROX1 prevented the accumulation of the LC3-contain-
ing early autophagosomes in the presence of the lysosomal in-
hibitor bafilomycin A or chloroquine, which inhibit the fusion of
autophagosomes with the lysosomes (Figure 7D). Importantly,
we observed a decreased number of LC3-containing early auto-
phagosomes under hypoxia in lentivirally PROX1-silenced
SW480R or SW1222-PROX1high cells when their fusionwith lyso-
somes was inhibited (Figure 7E), suggesting that PROX1 en-
hances the autophagic flux. The addition of a low concentration
of chloroquine or bafilomycin A resulted in loss of the Lgr5+ cells
after Apc deletion (Figure 7F). Of note, this chloroquine concen-
tration inhibited the formation of VApcD/D organoid colonies
upon subculture, but not their survival when added 2 days after
organoid plating (Figure 7G). Furthermore, the addition of chloro-
quine or bafilomycin at a low dose to the LApcD/D organoid cul-
tures reduced the proportion of viable organoids to the same
level as Prox1 deletion in the LApcPD/D cultures, thus high-
lighting the important role of autophagy in promoting tumor cell
survival specifically in the Prox1+ cells (Figure 7H).
DISCUSSION
Prox1 is critical for the fate of several types of stem and progen-
itor cells (Elsir et al., 2012). Here, we show that Prox1 is not ex-
pressed in the Lgr5+ stem cells of normal intestinal crypts, but
is induced soon after the initiating mutation in intestinal tumori-
genesis. We show that the Prox1+ cells give rise to more differ-
entiated Prox1 cells in the adenomas, but not in the normal
intestine, indicating that a subpopulation of the Prox1+ cells
has cancer stem cell activity. Upon Prox1 deletion, the number
of stem cells declined and this was reflected later on as
decreased overall tumor cell proliferation and tumor growth.
Stem-like cells provide an important drug target in cancer, as
they are able to persist in tumors as a distinct population, self-
renew, and differentiate, and they are associated with tumor
relapse (Sampieri and Fodde, 2012). Therefore, development
of specific therapies targeted at cancer stem cells may improve
survival. In elegant studies, Schepers et al. demonstrated that
the Lgr5+ cells in intestinal adenomas have stem cell properties
(Schepers et al., 2012). Interestingly, recent studies indicated
that intestinal adenomas contain fewer stem cells than Lgr5+
cells, suggesting that only a subpopulation of the Lgr5+ cells
function as stem cells (Kozar et al., 2013). Furthermore, Myant
et al. have shown that the Rac1GTPase is an important regulator
of the proliferation of the Lgr5+ cell population in intestinal ade-
nomas (Myant et al., 2013). Although the Lgr5+ cells may be
dispensable for homeostasis of the normal intestine and for
increased proliferation of intestinal epithelium after Apc deletion
(Metcalfe et al., 2014), the expansion of cells derived from the
Lgr5+ cells in adenomas after Apc deletion clearly indicates
that they contribute to tumor growth (Schepers et al., 2012).
Importantly, Prox1 deletion not only decreased the number of
Lgr5+ cells in intestinal adenomas in vivo, but it also reduced their
proliferation, the organoid-initiating frequency and the number of
megacolonies and lumens in the glandular CRC organoids,
which all represent indicators of cancer stem cells (Ashley
et al., 2013). Furthermore, PROX1 silencing after the tumor
establishment resulted in a decrease of the LGR5+ tumor cell
marker before a decline in the overall tumor growth rate.
Mechanistically, we show that the phospholipid-binding pro-
tein Anxa1 is increased by the Wnt pathway activation after
Apc deletion, while Prox1 suppresses its expression. ANXA1
and PROX1 showed also mutually exclusive expression patterns
in human CRC samples. Strikingly, the silencing of ANXA1 in the
PROX1 cells mimicked the effects of PROX1 in the CRC cells.
Among its other effects, ANXA1 inhibits the proinflammatory
phospholipase A2, which has been shown to stimulate the prolif-
eration of CRC cells by producing various lipid mediators and
which regulates intercellular junctions and the actin cytoskeleton
(Cristante et al., 2013; Parente and Solito, 2004; Surrel et al.,
2009). Both ANXA1 silencing and PROX1 expression increased
stem cell markers and the number of LGR5+ cells in tumor orga-
noids and enhanced lumen formation, proliferation of tumor cells,
and tumor growth in vivo. Furthermore, ANXA1 silencing and
PROX1 expression increased FLNA, which stabilizes the cortical
3D actin networks, links them to the transmembrane receptor b1
integrin, and functions as a central mechanotransduction
element of the cytoskeleton (Ehrlicher et al., 2011; Zhou et al.,
2010). The role of the actin cytoskeleton in the expansion of the
adenoma stem cell population was supported by our FLNA re-
sults, showing that silencing this actin-binding protein, which
was expressed in the Lgr5+ stem cells of intestinal adenomas,
dramatically inhibited the activity and proliferation of the ade-
noma/CRC stem cells in 3D, but not in 2D, culture conditions.
FLNA is one of the markers of a CRC subtype characterized by
poor disease-free survival (Sadanandam et al., 2013). FLNA
expression is increased in a number of cancers, and it has
been recently shown to boost the hypoxia response and tumor
progression (Zheng et al., 2014). Consistent with this, the
FLNA-expressing PROX1+ tumor cells were more resistant to
apoptosis than the FLNAlow PROX1 tumor cells both in vivo
and in the organoids. There was a striking increase in apoptosis,
particularly in the central parts of the PROX1-silenced tumors
growing subcutaneously in mice. However, the sensitivity of the
PROX1 tumor cells to apoptosis was not due to insufficient
expression of angiogenic growth factors, as shown by the
inability of VEGF overexpression to rescue the difference.
Instead, the analysis of autophagy markers and use of lysosomal
inhibitors of autophagy indicated that PROX1 expression sus-
tains autophagy, which is known to be essential for the survival
of CRC cells (Sato et al., 2007). This finding is particularly
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Figure 7. Loss of PROX1 Reduces CRC Stem Cell Survival under Unfavorable Conditions
(A) Percentage of caspase-3+ apoptotic cells among the E-cadherin+ epithelial cells in VApcD/D (black columns) and Prox1-deleted (VApcPD/D; red columns)
organoids 8 days after the addition of 4-OH-Tam and 6 days after the removal of R-Spondin1 (right panel, n = 14) or growing subcutaneously in NSG mice
(left panel, n = 22).
(B) Active caspase-3 staining of subcutaneously growing Scr and shPROX1-transduced SW1222-PROX1high tumors in NSG mice. Note that the shPROX1-
transduced tumor interior is highly apoptotic (asterisk).
(C and D) Immunoblotting of SW480R-sh cells for the indicated proteins. Cells were either cultured in complete medium (C) or in starvation medium lacking amino
acids 8 hr before protein isolation (D) in the absence or presence of 100 nM bafilomycin A or 30 mM chloroquine.
(E) The number of LC3+ granules in the indicated cell lines transduced with Scr or shPROX1 lentivirus and cultured in starvation medium containing 100 nM
bafilomycin in hypoxia for 8 hr (n = 50).
(F) Flow cytometric analysis of the Lgr5-EGFP+ cells in LApcD/D organoids, 9 days after the Apc deletion and 3 days after the addition of 15 mM chloroquine or
0.2 mM bafilomycin A.
(G) The plating efficiency and survival percentage of VApcD/D organoids in the presence or absence of chloroquine or bafilomycin A. Note that for organoid
survival chloroquine or bafilomycin were added 2 days after organoid splitting for 3 days.
(legend continued on next page)
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interesting considering that hypoxia-induced autophagy can pro-
mote tumor cell survival and adaptation to antiangiogenic treat-
ment, which is used in CRC therapy (Hu et al., 2012). Our results
are in agreement with the findings of Ragusa et al., who show that
PROX1 promotes the metabolic adaptation of CRC cells in unfa-
vorable microenvironments, and thus critically contributes to the
metastatic outgrowth of CRCs (Ragusa et al., 2014).
In summary, we show here that PROX1 is induced in intestinal
stem cells in adenoma/CRC soon after the activation of the Wnt
pathway. While the APC mutation induces both PROX1 and
ANXA1 expression in the epithelium, PROX1 restricts ANXA1
levels and induces FLNA, which stimulates cell proliferation
and promotes stem cell activity in the adenomas, andmay coun-
teract stem cell exhaustion during tumor growth. The net effect is
the expansion of the adenoma/CRC stem cell population and
increased tumor growth. In the hypoxic parts of tumor trans-
plants, PROX1 promotes tumor cell survival by increasing auto-
phagy. Based on this study, PROX1 regulates the number of
adenoma/CRC stem cells without affecting the homeostasis of
the normal intestine, thus providing an attractive therapeutic
target pathway for drug development in CRC.
EXPERIMENTAL PROCEDURES
A detailed description of the experimental procedures is provided in Supple-
mental Experimental Procedures.
Intestinal Crypt/Organoid Cultures
The National Board for Animal Experiments at the Provincial State Office of
Southern Finland approved all experiments performed with mice. Intestinal
crypts from Apcflox/flox; villin-CreER, Apcflox/flox; Prox1flox/flox (Harvey et al.,
2005); villin-CreER, Csnk1a1flox/flox; tp53flox/flox; villin-CreER (Elyada et al.,
2011), Apcflox/flox; Lgr5-EGFP-IRES-CreER (Barker et al., 2007) and Apcflox/flox;
Prox1flox/flox; Lgr5-EGFP-IRES-CreER mice were isolated and cultured as
described previously (Sato et al., 2009, 2011). To activate the endogenous
b-catenin/TCF pathway in mouse organoids, cultures were treated with
300 nM 4-hydroxy-tamoxifen (4-OH-Tam) for 48 hr. Organoids with the endog-
enously active b-catenin/TCF pathway were then selected and cultured in
growth factor-deficient medium.
Human Organoid Cultures
For 3D culture, SW1222 or patient-derived CRC cells were extensively trypsi-
nized, embedded into Matrigel (500–2,000 cells/50 ml Matrigel/well), and
grown for 3–16 days. The ethics committee of the Department of Surgery at
Helsinki University Hospital approved all experiments involving patient sam-
ples, and informed consent was obtained from the patients. Tissue samples
isolated from CRC patients were processed according to a previously pub-
lished method (Sato et al., 2011).
In Vivo Experiments
Mice were injected with 2 mg tamoxifen (Sigma) dissolved in 200 ml sunflower
oil (Sigma) at the age of 8–9 weeks. The mice were euthanized at the indicated
time points. The mice were on the C57Bl/6 background. In all experiments
littermate controls were used.
Statistical Analysis
Statistical comparison of two groups was done by two-tailed unpaired or
paired t test using the SPSS software unless otherwise indicated. For nonpara-
metric tests, theMann-WhitneyU test was used, and the data are presented as
boxplots, showing the five statistics (minimum, first quartile, median, third
quartile, maximum). The statistical significance is marked by *p < 0.05, **p <
0.01, and ***p < 0.005.
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